&w=3840&q=100)
Nifty logs 4.2% weekly gain on trade optimism, RBI rate cut hopes
India's benchmark Nifty ended the week with a 4.2 per cent rise, marking its best weekly run since April 18, as investors cheered a truce with Pakistan, trade talks with the United States (US), and expectations of domestic interest rate cuts.
The Nifty ended at 25,020, down 42 points or 0.17 per cent, while Sensex ended Friday's session at 82,331, down 200 points or 0.24 per cent, paring its weekly gain to 3.6 per cent.
The week began with the Sensex and Nifty posting their largest single-day gains in over four years, following a ceasefire agreement between India and Pakistan.
Investors heaved a sigh of relief as the ceasefire eased concerns about the economic impact of a potential war breaking out between the two nuclear-armed neighbours.
However, profit booking during the week dragged the indices down, fuelled by concerns that foreign portfolio investors (FPIs) may redirect funds to China and the US following the trade tariff truce.
During the week, the US and China agreed to slash reciprocal trade tariffs for 90 days, with the US reducing duties on Chinese imports from 145 per cent to 30 per cent, while China trimmed its tariffs on US goods from 125 per cent to 10 per cent.
This China-US deal sparked fears that foreign portfolio investor flows could move away from India. In April, India emerged as a haven amid global trade uncertainties, attracting foreign investments.
Markets rose again later in the week after US President Donald Trump said India had offered to drop tariffs on US goods on Thursday. Following the sharp rise, experts believe, markets could remain range-bound going ahead.
"The broader consolidation with a positive bias is likely to persist for the Indian markets, supported by easing geopolitical tensions, progress on trade agreements, and improving signs of macroeconomic stability," said Siddhartha Khemka, head of research for wealth management at Motilal Oswal Financial Services.
The market breadth was positive on Friday, as the broader markets outperformed. The Nifty Midcap 100 index rose about a per cent, while the Nifty Smallcap index rallied close to 2 per cent. About 2,542 stocks advanced and 1,449 declined on the BSE.
Bharti Airtel, which fell 2.8 per cent, was both the worst-performing Sensex stock and the biggest drag on the Sensex. The stock declined a day after over $1 billion stake sale by large shareholder Singapore Telecommunications.
Domestic and foreign portfolio investors (FPIs) were the big buyers on Friday. FPIs were net buyers worth ₹8,831 crore, their biggest purchase since March 27, while domestic institutions were the net buyers worth ₹5,187 crore, their biggest since May 9.
The Airtel mega block deal influenced the FPI and DII investment tally.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
15 minutes ago
- Mint
Trump wants cheaper drugs like Europe has. How it works.
President Donald Trump doesn't just want to bring down prescription drug prices for Americans. He wants European countries to raise them to make up the revenue that drugmakers would lose from his policy. Trump is proposing a so-called most-favored-nation pricing model, which would set U.S. drug prices at the lowest level in other wealthy countries. But the pharmaceutical industry isn't buying into tying drug prices in the U.S. to prices in Europe—at least not knowing the details of the president's proposal. More details about the government's pricing model could come this week. On May 12, Trump directed government health officials to benchmark drug prices to international standards within 30 days. The lobbying group PhRMA, with members including U.S. pharma giants Eli Lilly, Pfizer, Johnson & Johnson, and AbbVie, has argued there are two reasons why U.S. drug prices are high: foreign countries not paying 'their fair share" for medicines, and middlemen such as pharmacy-benefit managers. Today, U.S. drug pricing is largely market driven. It involves negotiations between drug manufacturers, pharmacy-benefit managers, healthcare insurers and providers. European countries do it much differently. Each has its own way of determining drug prices, but most follow one of two broad approaches. The first approach, which Germany and France use, considers the overall clinical effectiveness of a new medicine. How does the new treatment compare to existing ones? Does it have added therapeutic benefits? If the new drug is substantially better, its price would reflect that. A second approach, used by the U.K., the Netherlands, and Sweden, analyzes cost effectiveness. This model not only compares the new drug to existing ones but also assesses the incremental value that the medicine brings to the health system. After the assessments, negotiations between drugmakers and the countries begin. Because many European countries have national health systems, they are in a strong negotiation position. If government negotiators think a medicine is too expensive for its effectiveness, they won't recommend its use. How Trump's MFN policy would work in practice isn't clear. Drug prices would probably be based on list prices in Europe since the prices paid by national health systems, or net prices, are confidential. The president's open-ended directive, laid out in an executive order, has many wondering how the U.S. could raise prices in Europe. Trump has made clear he wants to close the gap between U.S. and international prices, and has suggested he would use tariffs and export controls to achieve his goal. In theory, drugmakers could set list prices higher in Europe as long as it doesn't affect net prices, health policy expert Dr. Huseyin Naci told Barron's. In the U.K., for example, a higher list price could still lower the prices in other European countries. 'So that would still not be an acceptable approach to many other European countries," said Naci, who is associate professor of health policy at the London School of Economics. Overhauling Europe's decades-old pricing approaches would require fundamental changes to their pricing regulations—and there will be 'little appetite or ability" to alter them, Naci added. Cost is another complicating factor. 'Pharmaceutical spending is already one of the top categories of spending in many countries in terms of healthcare expenditure, so there's little room to accommodate higher prices and spending for pharmaceuticals in Europe," according to Naci. How Trump is planning to make Europeans pay more for drugs is the big question. He could use tariffs and trade negotiations as leverage. In early April, the president said a 'major" tax on pharmaceutical imports is coming 'very shortly," however nothing has been announced yet. In a trade agreement with the U.K. a month later, there is a provision on pharmaceuticals that states the U.K. will 'endeavor to improve the overall environment for pharmaceutical companies." What that means in practice still isn't clear. Write to Elsa Ohlen at
United News of India
16 minutes ago
- United News of India
Rupee rises by 7 paise against USD
Mumbai, June 12 UNI) The rupee on Thursday further appreciated by 7 paise at 85.44 in the opening session on weak demand for US dollar by bankers and importers amid strong capital inflow, forex traders said. This appreciation comes amid various global and domestic economic factors influencing the currency markets, traders added. The Indian rupee opened 8 paise up at 85.43 against the US dollar against Wednesday close of 85.51 The partially convertible rupee recorded intraday high and low at 85.40 and 85.48 respectively, dealers added. UNI JS PRS
Time of India
16 minutes ago
- Time of India
‘Investors from US, Middle East interested…': Adani Airport Holdings may raise $1 billion in equity; first time from external investor
The airport division, which is entirely owned by Adani Enterprises Ltd, has an estimated value of $20 billion. Adani Airport Holdings Ltd (AAHL) is considering raising approximately $1 billion in equity from international investors whilst assessing expansion strategies and possible acquisitions, Adani Group CFO Jugeshinder Singh has said. The airport venture will be seeking external investor equity funding for the first time. The airport division, which is entirely owned by Adani Enterprises Ltd, has an estimated value of $20 billion, according to sources quoted in an ET report. This valuation surpasses GMR Airport's market capitalisation of $10.4 billion. GMR operates airports across various locations including New Delhi, Hyderabad, Goa and Nagpur. AAHL, which holds the position of India's largest private airport operator, currently manages seven airports - Mumbai, Ahmedabad, Lucknow, Mangaluru, Jaipur, Guwahati and Thiruvananthapuram. The company is completing its eighth airport in Navi Mumbai, scheduled to commence operations in August. Adani Airport Holdings Seeks International Investors "Everyone wants to do airports with us - investors from the US, Middle East and Australia have evinced interest in investing in the business," said Sagar Adani, nephew of group chairman Gautam Adani. Sagar Adani is also executive director, Adani Green Energy. CareEdge Ratings estimates that India's air passenger traffic will grow at 9% CAGR between FY25 and FY27, reaching a volume of 485 million. Adani Airports Across India According to the Directorate General of Civil Aviation, India's domestic air passenger traffic showed a 10.35% yearly increase in FY25. Airlines transported 14.54 million passengers across their routes. AAHL plans to capitalise on this growth by expanding its infrastructure, particularly with airports in Mumbai-Navi Mumbai and other strategic locations, aiming to triple its capacity over the next 15 years. Also Read | Big worry! China's grip over rare earth magnets sends Indian auto industry into a spin; delegation of industry people eye China visit Whilst the company maintains sufficient funding at present, it remains open to securing additional capital based on timing and market circumstances. Adani CFO Singh indicated uncertainty about their immediate plans, saying, "We also have not decided whether we want to do it or not yet. So what we are thinking about is — is it a good idea for us to do it right now or should we wait two-three years once the build-out happens and the value is established." In January, Abu Dhabi Investment Authority (ADIA) provided an investment of ₹6,300 crore to GMR Enterprises (GEPL), the promoter entity of GMR Group, to decrease their debt burden. Regarding expansion plans, Singh said, "We are open to acquisitions in India and internationally. For international deals, it will have to be an international city pair which caters to an Indian diaspora. If there's a lot of Indian passengers going to a specific airport in some other city in the world, and if that opportunity comes up, we will look at that." The organisation plans to establish the airport business as an independent subsidiary within the next two-three years, before proceeding with its listing. AAHL reported a 7% increase in passenger traffic, handling 94 million passengers in FY25 compared to FY24. Also Read | 'Better than America…': Nitin Gadkari asserts India's roads to be comparable to US in 2 years, adds 'main picture yet to start' Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
